Liver Disease in the Pharmacy: Recognising Risk and Knowing When to Refer
How to identify patients at risk of undiagnosed liver disease, which symptoms require urgent action, and how to navigate referral pathways for MASLD, cirrhosis, viral hepatitis, and drug-induced liver injury.
Why this matters
Liver disease causes approximately 10,000 deaths per year in England, and the UK has one of the highest rates of liver disease mortality in Western Europe. Unlike most other major organ diseases, liver disease mortality has risen significantly over recent decades. The three most common causes are alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease), and chronic viral hepatitis due to hepatitis B or C infection.
Many patients with significant liver fibrosis or even compensated cirrhosis have few or no symptoms. By the time jaundice, ascites, or a variceal haemorrhage develops, the disease has usually progressed to a late and potentially irreversible stage. Recognising which patients collecting prescriptions have unaddressed risk factors and have not been assessed is where community pharmacy can make a real difference.
Community pharmacists are well placed to do this. Patients with type 2 diabetes, metabolic syndrome, or obesity collect repeat prescriptions regularly, often for years, without ever receiving a liver disease review. Patients taking potentially hepatotoxic medicines need periodic monitoring, and the pharmacist is well positioned to check whether that monitoring is in place. When symptoms do appear, knowing whether they represent a 999 emergency, a same-day referral, or a routine GP conversation can directly influence the outcome.
One practical illustration: a 58-year-old man collecting metformin and atorvastatin mentions over several months that he is getting more tired and that his waistband feels tighter. He attributes this to getting older. On the day he asks for a wind remedy, the pharmacist notices his abdomen looks distended and he is slightly pale. He is advised to contact his GP the same day for assessment of possible ascites. He is subsequently found to have cirrhosis secondary to MASLD, previously unsuspected.
A second example: a patient collecting long-term nitrofurantoin for recurrent urinary tract infections mentions that she has been feeling increasingly tired and itchy for several months. Review of her monitoring records reveals no liver blood tests in over two years. A prompt to her GP leads to investigation and an early diagnosis of nitrofurantoin-induced liver injury. Both presentations share a common thread: the patient came in for a routine reason, and the pharmacist made the connection.
Red flags vs more likely benign
| Feature | More likely benign | Red flag ⚠ |
|---|---|---|
| Skin and sclera | Normal skin and eye colour | Yellowing of the skin or whites of the eyes (jaundice): always requires prompt assessment |
| Urine and stools | Normal urine and stool colour | Dark tea-coloured urine and pale or grey stools alongside jaundice: suggests cholestasis or biliary obstruction |
| Jaundice with fever | Mild self-limiting illness without jaundice | Jaundice accompanied by fever, rigors, or severe right upper quadrant abdominal pain: may indicate acute cholangitis, acute hepatitis, or sepsis. Requires urgent same-day medical assessment. |
| Itching (pruritus) | Mild, localised, with a clear skin cause | Persistent generalised itch without a skin rash, particularly at night: a recognised feature of cholestatic liver disease; patients often present requesting antihistamines or emollients without making the link |
| Abdomen | No swelling; mild discomfort without distension | Visible abdominal swelling (possible ascites), right upper quadrant tenderness, or a noticeably enlarged and tender liver |
| Gastrointestinal bleeding | No blood in vomit or stool | Vomiting blood or passing black tarry stools (melaena): possible variceal haemorrhage; call 999 immediately |
| Mental state | Alert, orientated, and behaving normally | Confusion, drowsiness, altered behaviour, or slurred speech in a patient with known liver disease: possible hepatic encephalopathy |
| Bleeding tendency | No unusual bruising or prolonged bleeding | Easy bruising, spontaneous bleeding, or prolonged bleeding from minor cuts in a patient who is also jaundiced or unwell: possible coagulopathy in acute liver failure |
| Weight and appetite | Mild fluctuation; short-term appetite change during illness | Progressive unintentional weight loss with persistent fatigue, poor appetite, or upper abdominal discomfort |
| Physical signs | An incidental single spider naevus on the face or chest is common in healthy adults and not necessarily significant | Multiple spider naevi, pronounced palmar erythema (redness of both palms), caput medusae, or marked muscle wasting of the temples or upper limbs |
| Medicines and liver tests | Stable liver blood results on a long-established medicine with no new symptoms | New rise in liver enzymes, or new jaundice, after starting or dose-increasing a potentially hepatotoxic medicine: possible drug-induced liver injury (DILI) |
Identifying patients at increased risk: who to flag for GP review
Significant liver disease can be present without any symptoms. The pharmacist's role is to recognise patients with established risk factors who have not been assessed, and to prompt review before complications develop.
- Common over-the-counter presentations that may indicate liver disease: community pharmacists often see liver disease before it has been diagnosed because patients present for seemingly unrelated reasons. Consider asking about liver disease when a patient requests: antihistamines or emollients for persistent generalised itch with no obvious skin cause; wind relief or bloating remedies; fatigue supplements or iron without a clear reason; indigestion remedies that are failing to help; advice about dark or tea-coloured urine; or remedies for unexplained bruising. In each case, ask directly: any yellowing of the skin or eyes? Pale stools? Abdominal swelling? Any alcohol use? Known liver condition?
- Type 2 diabetes and metabolic syndrome: NICE NG49 recommends clinicians be aware that MASLD is more common in people with type 2 diabetes or metabolic syndrome. Consider whether liver disease risk has previously been assessed, and prompt a GP review if not. A useful opening question: have you ever been told you have fatty liver disease, abnormal liver blood tests, or liver scarring?
- Obesity (body mass index of 30 kg/m2 or above): a recognised risk factor for cirrhosis in NICE NG50. Sustained weight loss through diet and regular exercise remains the cornerstone of MASLD management. GLP-1 receptor agonists (such as semaglutide) are increasingly used in MASLD management and may be encountered in prescriptions.
- Significant alcohol use: ask about weekly units during medicines review. The Chief Medical Officers advise no more than 14 units per week for both men and women. NICE NG50 uses thresholds of 50 or more units per week in men and 35 or more in women to trigger cirrhosis screening. The AUDIT-C questionnaire is a practical counter-based screening tool. Caution: patients with established alcohol dependence should seek medical support before attempting to stop drinking abruptly, as alcohol withdrawal can be life-threatening.
- Viral hepatitis risk: several groups warrant GP referral for testing if unscreened: anyone with a history of injecting drug use, even once; people who have been imprisoned; those experiencing homelessness; people who received blood products or organ transplants before universal screening was introduced; those born in or who received healthcare in countries with high hepatitis B or C prevalence; and those with close household or sexual contact with a known carrier. Modern direct-acting antiviral therapy can cure more than 95% of hepatitis C infections.
- Family history and inherited liver disease: a family history of haemochromatosis, unexplained cirrhosis, or other inherited liver disease warrants GP discussion, particularly if the patient also has abnormal liver tests, fatigue, or joint pain. Haemochromatosis is a relatively common inherited cause of liver disease in the UK and may present with abnormal liver tests, diabetes, bronze skin discolouration, or joint pain before frank liver failure develops.
- Hepatitis B vaccination: when identifying patients at risk of hepatitis B (household contacts of a known carrier, people who inject drugs, men who have sex with men, and certain occupational or travel risk groups), consider that hepatitis B vaccination may be indicated and has not been offered.
- Potentially hepatotoxic medicines: several commonly dispensed drugs carry a risk of liver injury. Examples include: methotrexate (requires regular monitoring and fibrosis surveillance); amiodarone (progressive liver damage can occur even years into treatment); sodium valproate; nitrofurantoin on long-term use; and isoniazid. Repeated use of higher-than-recommended doses of paracetamol over several days can also cause serious liver injury without a single large overdose, particularly in people who are underweight, malnourished, or drink excess alcohol. Ask about herbal and traditional medicines. Products associated with significant liver injury include green tea extract supplements, kava, black cohosh, some herbal preparations marketed for liver health, and a range of traditional Chinese and Ayurvedic preparations. Bodybuilding supplements are a growing cause of serious drug-induced liver injury. Check whether liver blood test monitoring is current; if there is no recent result, prompt a GP review.
Normal liver blood tests do not rule out significant liver disease. NICE NG49 is explicit: routine liver blood tests should not be used to exclude MASLD or to assess for advanced fibrosis.
🛑 STOP Before Reassuring
When a patient presents with a possible liver-related concern, or when reviewing a patient with metabolic or alcohol-related risk factors, run through this quick counter framework.
Jaundice (skin or eyes)? Fever with jaundice or upper abdominal pain? Persistent generalised itch? Abdominal swelling? Confusion or drowsiness in a patient with liver disease? Vomiting blood? Unusual bruising?
Alcohol above 14 units per week? Hepatotoxic medicine (methotrexate, amiodarone, sodium valproate, nitrofurantoin, isoniazid, paracetamol overuse)? Herbal supplements (green tea extract, kava, black cohosh, high-dose milk thistle)? Bodybuilding supplements?
Type 2 diabetes or metabolic syndrome? Obesity? Viral hepatitis risk (injecting drug use, imprisonment, healthcare abroad)? Family history of haemochromatosis or unexplained cirrhosis? Known MASLD without recent review?
999 for emergency features. Same-day GP for new jaundice, fever with jaundice, new ascites, confusion in liver disease, or suspected DILI. If same-day GP is unavailable, advise NHS 111. Routine GP review for unmonitored risk factors, overdue blood tests, or family history.
Patients often mention dark urine only after being directly asked. Family members may notice yellowing of the eyes before the patient does. Ask both questions specifically when liver disease is suspected.
Non-invasive liver fibrosis assessment: what happens in primary care
When a patient with metabolic or other risk factors is identified, regardless of whether liver enzymes are normal or abnormal, primary care pathways use non-invasive tools to risk-stratify before considering referral.
- Enhanced Liver Fibrosis (ELF) test: NICE NG49 recommends the ELF test as the preferred tool for assessing advanced fibrosis in people with MASLD. An ELF score of 10.51 or above is associated with an increased likelihood of advanced fibrosis and should trigger specialist assessment according to local pathways. Patients with an ELF score below 10.51 are unlikely to have advanced fibrosis and should be reassessed every three years.
- FIB-4 index: many NHS primary care pathways use the FIB-4 index as a first-step triage tool before ELF testing, because it can be calculated from routine blood results (age, alanine aminotransferase [ALT], aspartate aminotransferase [AST], and platelet count) at no additional cost. A score below 1.30 makes advanced fibrosis unlikely; a score above 2.67 indicates higher risk. Age-adjusted thresholds apply: the lower cutoff of 2.0 is used for patients over 65 years, as FIB-4 rises with age independently of liver disease.
- Transient elastography (FibroScan): used in specialist hepatology services and increasingly in community diagnostic centres and local liver assessment pathways to measure liver stiffness as a direct marker of fibrosis. Patients referred with a high FIB-4 or ELF score will typically undergo this assessment before a liver biopsy is considered.
- Hepatocellular carcinoma (HCC) surveillance: all patients with confirmed cirrhosis should be under specialist hepatology review. NICE NG50 recommends six-monthly liver ultrasound surveillance for HCC in all patients with cirrhosis. If a patient with known cirrhosis mentions they have not had a scan recently, check they remain engaged with their hepatology follow-up.
Not all jaundice or abdominal swelling indicates liver parenchymal disease. Biliary obstruction from gallstones, pancreatic disease, or malignancy can present identically to liver disease. Heart failure is also a recognised cause of ascites and peripheral oedema.
What to do in pharmacy
Key takeaways
- Significant liver disease can be present without any symptoms: the pharmacist's role is to identify at-risk patients collecting repeat prescriptions and prompt GP review before complications develop.
- Jaundice with fever or rigors, variceal bleeding, and hepatic encephalopathy all require urgent or emergency action. Do not offer over-the-counter reassurance for any of these presentations.
- Normal liver blood tests do not exclude significant liver disease. NICE NG49 is explicit on this point, and many patients with advanced fibrosis have entirely normal routine liver enzymes.